Monday, April 28, 2025 4/28/2025

Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflows

Award Number: R44GM112241
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflows - Development of a high-throughput screen to detect the effects of both pre- and post- biotransformed compounds for enhanced content drug discovery workflows Project Summary This Small Business Innovation Research Phase II project will build upon our successful Phase I demonstration that substrate-free autobioluminescent signal generation can detect both the pre- and post-biotransformed metabolic impacts of therapeutic compounds from a single plate-based assay. Here, we will leverage this technology to develop a panel of industry-relevant autobioluminescent cell lines optimized for the detection of pre- and post-biotransformed compound metabolic impacts and the identification of specific detoxification pathway activation using modern three-dimensional (3D) microphysiological culture systems. These products and their underlying technology will specifically address the National Institute of General Medical Sciences (NIGMS) request for novel in vivo and in vitro methods for predicting the safety and toxicities of pharmacologic agents. By optimizing this technology to function within the industry-preferred 3D microphysiological format, we will address the critical need for new methods that can both identify compound toxicity and elucidate the mechanisms through which cells mitigate the compounds’ effects. The autonomous nature of this technology will increase toxicological data acquisition while preserving the critical advantage of presenting physiologically- relevant data, and reducing the cost of performance by eliminating substrates, reducing complexity, limiting hands-on operation time, obviating the need for sample destruction, and reducing the potential for measurement error. Through the validation of this technology at a scale relevant to tier 1 drug discovery screening and its comparative analysis against the existing gold-standard ATP content assay, this revolutionary approach is poised to have a significant and immediate impact towards reducing the estimated $8B/year in unnecessary expenditures made by pharmaceutical companies during their development of the 48% of new compounds that fail at the Phase I clinical trial stage due to misidentification of toxicological effects during tier 1 screening. This is possible because, as demonstrated in our Phase I work, the use of our autobioluminescent technology overcomes the high economic and logistical costs of existing, traditionally-bioluminescent cell’s requisite chemical substrate addition, which must co-occur with each generation of signal, and the intensive hands-on time necessitated to scale cultures due to their requisite sample destruction concurrent with imaging. Similarly, our autobioluminescent technology also obviates the hurdles presented by fluorescent cell’s susceptibility to autofluorescent signal inhibition and their tendency to remain active during downturns in cellular metabolism or even after cell death. The technology and products developed in this effort will therefore be capable of significantly improving the throughput and effectiveness of microphysiological systems-based tier 1 compound screening to improve the efficiency and economics of new compound development, and ultimately, consumer safety. This will allow them to thrive in a microphysiological system market that is predicted to maintain a compound annual growth rate of 70% to exceed $1.3B globally by 2022.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2018	490 BIOTECH INC	2450 EJ CHAPMAN DR	KNOXVILLE	TN	37996	KNOX	USA	Biomedical Research and Research Training	000	3	7/2/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2018	490 BIOTECH INC	2450 EJ CHAPMAN DR	KNOXVILLE	TN	37996	KNOX	USA	Biomedical Research and Research Training	000	3	8/12/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $473,892 )
2018	2018	490 BIOTECH INC	2450 EJ CHAPMAN DR	KNOXVILLE	TN	37996	KNOX	USA	Biomedical Research and Research Training	000	3	8/21/2018	NON-COMPETING CONTINUATION	$473,892
														Subtotal = $473,892

Issue Date FY: 2017 ( Subtotal = $522,620 )
2017	2017	490 BIOTECH INC	2450 EJ CHAPMAN DR	KNOXVILLE	TN	37996	KNOX	USA	Biomedical Research and Research Training	000	2	9/20/2017	COMPETING CONTINUATION	$522,620
														Subtotal = $522,620

Grand Total All Awards = $996,512

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflows

Award Number: R44GM112241

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer